Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target lowered by analysts at JMP Securities from $72.00 to $71.00. They now have a "market outperform" rating on the stock.
Biopharmaceuticals Packaging Market Size Expected to Reach USD 42.08 Bn by 2032 Wed, May 8, 2024, 5:32 PM GMT+2 17 min read 0 Advertisement Up next Halozyme's (HALO) Q1 Earnings Beat, Revenues Lag Estimates Wed, May 8, 2024, 4:34 PM GMT+2 3 min read 0 In
Halozyme to Participate in Upcoming Investor Conferences Wed, May 8, 2024, 2:30 PM GMT+2 2 min read 0 In this article: Advertisement Up next Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates Wed, May 8, 2024, 12:00
Halozyme to Participate in Upcoming Investor Conferences